Currently available oncology treatments involve general administration of chemotherapeutics, application of monoclonal antibodies specifically targeting tumor antigens, immunomodulating agents or modified CAR-T cells. Many different approaches used up to date showed their limitations – lack of specificity, severe adverse effects due to broad presence of targeted antigens in normal tissues, low tumor penetration particularly to the hypoxic regions, low targeting and penetration to metastases.

Cellis MDC technology aims to solve these unmet medical needs.






Cellis platform exploits immune cells (mainly macrophages) as live delivery systems of different molecules to solid tumors and metastases. Using this technology we may deliver radioisotopes, labels, drugs, small molecules and in this way either treat or diagnose tumors. Macrophages naturally migrate to the hypoxia avascular regions of the tumor and unload conjugated cargo. These regions are normally unreachable with the current therapies and are responsible for regrowth of the tumor. Cells used in this technology are immunologically not modified and delivery is based on the biological phenomenon discovered by our scientists.


Zdj 3

Cell-based drug delivery system - MDC (Macrophage-Drug Conjugate) for drug delivery. Cells used in our system show high ability in tumor homing and instant unloading features making drug delivery very efficient. 

zdj4 nowe

zdj do podmiany

Cell-based imaging system - MRIC (Macrophage-Radio Isotope Conjugate) is focused on the development of the novel diagnostic method using PET (positron emission tomography) of solid tumors, metastases and in particularly small/micro metastases. Early detection of cancer and/or its metastases represents a major challenge to improve therapeutic outcome.

Zdj 6



In 2016 European Research Council (ERC) dedicated grant for the investigation of the TRAIN mechanism and awarded this project as ONE of 10 the MOST INTERESTING PROJECTS IN THE ERC HISTORY.